================================================================================
                                  UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                     Form 10-Q

(Mark One)
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
    Act of 1934

For the quarterly period ended March 31, 1999, or

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities
    Exchange Act of 1934

For the transition period from _________________ to __________________

Commission file number      000-21615
                           ------------


                             BOSTON BIOMEDICA, INC.
           (Exact name of Registrant as Specified in its Charter)

     Massachusetts                                   04-2652826
------------------------                       ----------------------
    (State or other                               (I.R.S. Employer
    Jurisdiction of                               Identification No.)
      Incorporation or
     Organization)

   375 West Street,
   West Bridgewater,
     Massachusetts                                   02379-1040
------------------------                       ----------------------
 (Address of Principal                              (Zip Code)
  Executive Offices)

Registrant's telephone number, including area code    (508) 580-1900
                                                      --------------

  Indicate by check whether the registrant: (1) has filed all  reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter  period  that  the  registrant  was
required  to  file  such  reports),  and  (2)  has  been  subject to such filing
requirements for the past 90 days.

                                                         Yes [X]         No [ ]

  The number of shares outstanding of the  Registrant's  only  class  of  common
stock as of April 30, 1999 was 4,717,816.
================================================================================
<PAGE>


Part I. Financial Information

Item 1. Financial Statements



                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF OPERATIONS

                                   (Unaudited)

                                                    For the Three Months Ended
                                                             March 31,
                                                   ----------------------------
                                                       1999           1998
                                                   -------------  -------------

REVENUE:
     Products                                       $ 3,456,202    $ 3,063,359
     Services                                         3,388,963      3,209,436
                                                   -------------  -------------
            Total revenue                             6,845,165      6,272,795

COSTS AND EXPENSES:
     Cost of product sales                            1,808,647      1,771,751
     Cost of services                                 2,470,097      2,323,211
     Research and development                           762,609        432,389
     Acquired research and development                     -           850,000
     Selling and marketing                            1,005,271        928,612
     General and administrative                       1,094,690      1,029,936
                                                   -------------  -------------
            Total operating costs and expenses        7,141,314      7,335,899

            Loss from operations                       (296,149)    (1,063,104)

Interest income                                             696         24,530
Interest expense                                        (87,199)          (971)
                                                   -------------  -------------

            Loss before income taxes                   (382,652)    (1,039,545)

Benefit from income taxes                               145,408        395,027
                                                   -------------  -------------

            Net loss                                 $ (237,244)    $ (644,518)
                                                   =============  =============

            Net loss per share, basic                   $ (0.05)       $ (0.14)
            Net loss per share, diluted                 $ (0.05)       $ (0.14)

Number of shares used to calculate net loss per share
            Basic                                     4,717,816      4,632,061
            Diluted                                   4,717,816      4,632,061

   The accompanying notes are an integral part of the Consolidated Financial
                                   Statements

                                       2

<PAGE>


                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                           CONSOLIDATED BALANCE SHEETS

<TABLE>
<CAPTION>
                                                                           (Unaudited)
                                                                            March 31,      December 31,
                                                                           -------------   --------------
                                                                               1999            1998
                                                                           -------------   --------------

                               ASSETS
                               ------
CURRENT ASSETS:
<S>                                                                           <C>              <C>      
    Cash and cash equivalents                                                 $ 113,286        $ 146,978
    Accounts receivable, less allowances of $632,281 in 1999 and
       $623,710 in 1998                                                       6,151,929        6,086,693
    Inventories                                                               6,662,708        6,689,768
    Prepaid expense and other                                                   731,678          479,983
    Deferred income taxes                                                       842,407          847,268
                                                                           -------------   --------------
                Total current assets                                         14,502,008       14,250,690
                                                                           -------------   --------------

Property and equipment, net                                                   7,090,702        6,925,423

OTHER ASSETS:
    Goodwill and other intangibles, net                                       2,754,635        2,809,825
    Notes receivable and other                                                   92,548           96,447
                                                                           -------------   --------------
                                                                              2,847,183        2,906,272
                                                                           -------------   --------------
              TOTAL ASSETS                                                 $ 24,439,893     $ 24,082,385
                                                                           =============   ==============


                LIABILITIES AND STOCKHOLDERS' EQUITY
                ------------------------------------

CURRENT LIABILITIES:
    Accounts payable                                                        $ 1,932,434      $ 2,369,495
    Accrued compensation                                                      1,013,391        1,284,162
    Other accrued expenses                                                      675,225          795,642
    Current maturities of long term debt                                         15,951           15,569
    Deferred revenue                                                            690,760          690,760
                                                                           -------------   --------------
                Total current liabilities                                     4,327,761        5,155,628
                                                                           -------------   --------------

LONG-TERM LIABILITIES:
    Long term debt, less current maturities                                   5,307,702        3,988,602
    Other liabilities                                                           686,971          730,138
    Deferred income taxes                                                       137,612          139,363

STOCKHOLDERS' EQUITY:
    Common stock, $.01 par value; authorized 20,000,000 shares in
       1999 and 1998; issued and outstanding 4,717,816 in 1999 and
       4,667,816 in 1998                                                         47,178           46,678
    Additional paid-in capital                                               16,566,654       16,418,717
    Retained earnings                                                        (2,633,985)      (2,396,741)
                                                                           -------------   --------------
                Total stockholders' equity                                   13,979,847       14,068,654
                                                                           -------------   --------------
             TOTAL LIABILITIES & STOCKHOLDERS' EQUITY                      $ 24,439,893     $ 24,082,385
                                                                           =============   ==============
</TABLE>

   The accompanying notes are an integral part of the Consolidated Financial
                                   Statements

                                       3
<PAGE>



                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                      CONSOLIDATED STATEMENTS OF CASH FLOWS

                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                  For the Three Months Ended 
                                                                           March 31,
                                                                 ----------------------------
                                                                     1999           1998
                                                                 -------------  -------------
CASH FLOWS FROM OPERATING ACTIVITIES:
<S>                                                                <C>            <C>        
    Net loss                                                       $ (237,244)    $ (644,518)
    Adjustments to reconcile net loss to net
       cash (used in) provided by operating activities:
    Depreciation and amortization                                     352,911        326,890
    Provision for doubtful accounts                                    (8,005)        50,756
    Deferred rent and other liabilities                               (43,167)       137,441
    Deferred income taxes                                               3,110        (21,937)
    Acquired research and development                                       -        850,000
Changes in operating assets and liabilities:
    Accounts receivable                                               (57,231)       607,845
    Inventories                                                        27,060       (475,762)
    Prepaid expenses                                                 (251,695)      (496,483)
    Accounts payable                                                 (437,061)      (266,116)
    Accrued compensation and other expenses                          (391,188)      (319,099)
    Deferred revenue                                                        -       (275,835)
                                                                 -------------  -------------
        Net cash used in operating activities                      (1,042,510)      (526,818)
                                                                 -------------  -------------

CASH FLOWS FROM INVESTING ACTIVITIES:
    Acquired research and development                                       -       (850,000)
    Additions to property and equipment                              (463,000)      (803,655)
    Advances under notes receivable and other assets                    3,899         11,950
                                                                 -------------  -------------
        Net cash used in investing activities                        (459,101)    (1,641,705)
                                                                 -------------  -------------

CASH FLOWS FROM FINANCING ACTIVITIES:
    Proceeds from long term debt                                    1,335,051              -
    Repayments of long-term debt                                      (15,569)          (403)
    Proceeds of common stock issued                                   148,437         39,250
                                                                 -------------  -------------
        Net cash provided by financing activities                   1,467,919         38,847
                                                                 -------------  -------------

DECREASE IN CASH AND CASH EQUIVALENTS:                                (33,692)    (2,129,676)
    Cash and cash equivalents, beginning of period                    146,978      2,772,360
                                                                 -------------  -------------
    Cash and cash equivalents, end of period                        $ 113,286      $ 642,684
                                                                 =============  =============
</TABLE>

   The accompanying notes are an integral part of the Consolidated Financial
                                   Statements

                                       4
<PAGE>


                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


(1)  Basis of Presentation
--------------------------

     The  accompanying  unaudited  consolidated  financial  statements have been
prepared in accordance  with generally  accepted  accounting  principles for the
interim financial information and with the instructions to Form 10-Q and Article
10 of Regulation  S-X.  Accordingly,  they do not include all of the information
and footnotes required by generally accepted accounting  principles for complete
financial statements. In the opinion of management,  all adjustments (consisting
of  only  normal  recurring   adjustments)   considered  necessary  for  a  fair
presentation  have been included.  Operating  results for the three months ended
March  31,  1999  are not  necessarily  indicative  of the  results  that may be
expected for the year ending December 31, 1999. For further  information,  refer
to the consolidated  financial  statements and footnotes thereto included in the
Form 10-K  filing  for the  fiscal  year  ended  December  31,  1998 for  Boston
Biomedica, Inc. and Subsidiaries ("the Company" or "Boston Biomedica").  Certain
prior years'  amounts in the  consolidated  financial  statements  may have been
reclassified to conform to the current year's presentation.

(2)  Use of Estimates
---------------------

     In conformity with generally accepted accounting principles,  management is
required to make estimates and assumptions  that affect the reported  amounts of
assets,  liabilities,  revenues,  and expenses for the periods  presented.  Such
estimates include reserves for uncollectable  accounts receivable as well as the
net  realizable  value of its  inventory.  Actual  results could differ from the
estimates and assumptions used by management.

(3)  Inventories
----------------

     Inventories consisted of the following: 

                                                    March 31,    December 31,
                                                       1999         1998
                                                    ----------   ----------

     Raw materials ..............................   $2,330,396   $2,407,154
     Work-in-process ............................    2,044,748    1,788,399
     Finished goods .............................    2,287,564    2,494,215
                                                    ----------   ----------
                                                    $6,662,708   $6,689,768
                                                    ==========   ==========



(4)  Segment Reporting and Related Information (all dollar amounts in thousands)
--------------------------------------------------------------------------------
     Selected  summarized  results for the Company's four operating segments are
as follows:

                                                         March 31,
          Segment revenue:                            1999       1998
          ----------------                         ---------------------
          Diagnostics                               $ 3,923    $ 3,619
          Clinical Laboratory Services                2,205      1,587
          Laboratory Instrumentation                  1,034      1,198
          Other                                         -          -
          Eliminations                                 (317)      (131)
                                                   ---------------------
            Total Revenue                           $ 6,845    $ 6,273
                                                   =====================


                                                         March 31,
          Segment operating (loss) income:            1999       1998
          --------------------------------         ----------------------
          Diagnostics                                   $ 145      $ (52)
          Clinical Laboratory Services                    146         69
          Laboratory Instrumentation                     (133)      (198)
          Other                                          (454)       (32)
          Acquired R&D                                      -       (850)
                                                   ----------------------
             Total (Loss) Income from Operations       $ (296)  $ (1,063)
                                                   ======================
 
                                      5

<PAGE>
                     BOSTON BIOMEDICA, INC. AND SUBSIDIARIES

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(4)  Segment Reporting and Related Information (Continued)
----------------------------------------------------------

                                                           March 31,  Dec. 31,
          Identifiable segment assets:                       1999       1998
          ----------------------------                    ----------------------
          Diagnostics                                       $ 16,403   $ 16,548
          Clinical Laboratory Services                         2,629      2,348
          Laboratory Instrumentation                           4,427      4,428
          Other                                                  981        758
                                                          ======================
              Total assets                                   $ 24,440   $ 24,082
                                                          ======================


(5)  Acquired Research and Development
--------------------------------------

     In March 1998, the Company acquired from BioSeq,  Inc.("BioSeq"),  the sole
and exclusive worldwide right to development stage technology, including the use
of BioSeq technical information, licensed processes and improvements to develop,
manufacture,  market and sell or sublicense products or services in the field of
human in vitro  immunodiagnostics.  In accordance with accounting  standards for
purchased  research and  development,  costs totaling  $850,000 were expensed in
that period. In September, 1998 the Company acquired 100% of the remaining stock
of BioSeq in a purchase  transaction.  See also the Company's most recent filing
on Form 10-K for the year ended December 31, 1998.

(6)  Computation of Net Income per Share
----------------------------------------

     In February 1997, the Financial Accounting Standards Board issued Statement
of Financial  Accounting  Standards ("SFAS") No. 128, "Earnings per Share". SFAS
128  establishes  a different  method of computing net income per share than was
required  under the  provisions of the previous  standard-Accounting  Principles
Board opinion No. 15. The following  illustrates  the  computation  of basic and
diluted net income per share.


                                            Quarter Ended March 31,
                                         --------------------------
                                            1999          1998
                                         ------------  ------------

Shares, basic                              4,717,816     4,632,061

Net effect of dilutive common stock
   equivalents-based on treasury stock
   method using average market price *        -             -

                                         ------------  ------------
Shares, diluted                            4,717,816     4,632,061
                                         ============  ============



Net loss, basic and diluted               $ (237,244)   $ (644,518)
                                         ============  ============

Net loss per share-basic                       (0.05)        (0.14)
Net loss per share-diluted                     (0.05)        (0.14)
                                         ============  ============


                * Potentially dilutive securities of 107,598 and
                246,148 were not included in the computation of
                diluted earnings per share because to do so would
                have reduced the loss per share for the three months
                ended March 31, 1999 and 1998, respectively.

                                       6

<PAGE>



Item 2.  Management's  Discussion  and  Analysis  of Results of  Operations  and
         Financial Condition.

Three Months Ended March 31, 1999 and 1998

     Total revenue  increased  9.1%, or $572,000,  to $6,845,000 for the quarter
ended March 31, 1999 from $6,273,000 in the prior year period. This increase was
the result of an increase in product sales of 12.8%, or $393,000,  to $3,456,000
from  $3,063,000  and an increase in service  revenue of 5.6%,  or $180,000,  to
$3,389,000  from  $3,209,000.  The increase in product revenue was primarily the
result of an overall sales increase of 9.4% in Quality Control Products,  due to
continued strong sales of Accurun(R) and custom (OEM) panel products,  partially
offset by a decline in  seroconversion  panel sales as a result of fewer ongoing
development  programs in the in vitro  diagnostic test kit industry.  Laboratory
instruments also showed a significant increase in revenue,  primarily related to
contract   manufacturing.   The  increase  in  service   revenue  was  primarily
attributable to the continued  growth in nucleic acid (molecular)  testing,  and
immunological  testing,  partially offset by a decline in service revenue at our
Laboratory  Instrumentation  segment as the  previously  announced  ABX modified
contract winded down to completion in the first quarter of 1999.

     Gross profit  increased  17.8% or $388,000,  to $2,566,000  for the current
quarter from $2,178,000 in the prior year period. Product gross profit increased
27.6% or  $356,000  to  $1,648,000  in 1999 from  $1,292,000  in the prior  year
quarter,  and product gross profit margin  increased to 47.7% of revenue in 1999
from  42.2%.  This  increase  was  primarily  the  result of  stronger  sales of
laboratory  instruments in 1999, while fixed costs remained relatively constant,
resulting in higher margins.  Service gross profit  increased 3.7% or $33,000 to
$919,000 in 1999 from $886,000 in the prior year, as margins remained relatively
steady,  declining  slightly to 27.1% in 1999 from 27.6% in 1998,  on the modest
revenue increase discussed above.

     Research and development expenses increased 76.4%, or $330,000, to $762,000
for the current  quarter from  $432,000 in the prior year  period.  The increase
relates  to  development  work  on the  Company's  pressure  cycling  technology
("PCT"), and increased expenditures in its drug discovery program.

     There was a one time  accounting  charge of $850,000 for the quarter  ended
March 31, 1998 related to the acquisition of the worldwide  exclusive  rights to
BioSeq, Inc.'s immunodiagnostic research and development technology.

     Selling and marketing  expenses  increased 8.3%, or $77,000,  to $1,005,000
for the current  quarter from  $928,000 in the prior year period.  This increase
was primarily attributable to increased personnel costs and marketing expenses.

     General  and  administrative   expenses  increased  6.3%,  or  $65,000,  to
$1,095,000  for the current  quarter from  $1,030,000  in the prior year period.
This increase was primarily a result of increased investor relations activities.

     The Company  generated  an  operating  loss of  ($296,000)  for the current
quarter versus a loss of  ($1,063,000)  in the prior year period.  The decreased
loss was primarily a result of the above mentioned one time accounting charge in
1998's first quarter.

     Net interest  expense of ($87,000) was incurred in 1999 versus an income of
$23,000 for the prior year period. The Company completed significant  investment
in  technology  and  infrastructure  during  the  first  half of  1998,  thereby
utilizing its cash  available to invest.  Since mid 1998,  capital  expenditures
have been funded primarily through the Company's line of credit.

     The Company  recorded a tax benefit in both quarters  based on the combined
federal and state statutory rate of 38%.

                                       7

<PAGE>


Liquidity and Financial Condition

     At  March  31,  1999,  the  Company  has  cash  and  cash   equivalents  of
approximately  $113,000  and  working  capital of  $10,176,000.  Trade  accounts
receivable  increased  $74,000 or 1% during the  quarter as  collections  lagged
expectations. Inventory decreased $27,000 to $6,663,000 as the Company continued
to focus its efforts on utilizing  existing inventory where possible rather than
purchasing raw materials for new products.

     The Company has  financed  its  operations  to date  through cash flow from
operations,  borrowings from banks and the sale of its common stock. The Company
expects its cash flow,  working  capital,  and  available  borrowings  under its
revolving line of credit to meet existing operational needs in 1999. The Company
has recently received approval for an increased  revolving line of credit of $10
million with more liberal financial covenants, which it expects to meet existing
operational needs for the foreseeable future. This facility will be collaterized
by  substantially  all assets of the Company  (excluding its real estate),  with
interest based on prime plus 1/4%


     Net cash used in  operations  for the three months ended March 31, 1999 was
$1,042,000  as compared to $527,000 in the prior year period.  This  decrease in
cash flow was primarily  attributable  to slower cash  receipts  compared to the
prior year.

     Cash used in investing activities for the three months ended March 31, 1999
was $459,000 as compared to  $1,642,000  in the prior year period.  The decrease
compared to the prior year was due primarily to a one time  technology  purchase
in the first quarter of 1998,  and lower  expenditures  in 1999 for property and
equipment, as the improvements at the Company's Maryland facility were completed
in 1998.

     Cash provided by financing  activities for the three months ended March 31,
1999 was  $1,468,000  as  compared  to  $39,000 in the prior  year  period.  The
increase  was  primarily  related  to the  increased  debt  from  the  company's
revolving line of credit incurred to finance  additional  working capital needs,
and property and equipment additions.

     The  Company  anticipates  significant  capital  expenditures  in  1999  to
continue as it plans to complete  renovations to its  manufacturing  facility in
Massachusetts,  as well as  implement a fully  integrated  business  information
system  ("ERP") at all  locations.  The  Company  believes  that  existing  cash
balances,  the borrowing  capacity available under the revolving line of credit,
and cash  generated  from  operations  are  sufficient  to fund  operations  and
anticipated  capital  expenditures  in  1999.  Except  for  purchase  orders  in
connection  with the  manufacturing  expansion  and ERP  system,  there  were no
material financial commitments for capital expenditures as of March 31, 1999.

Year 2000 Computer Systems Compliance

     The  following  disclosure  is a Year  2000  ("Y2K")  readiness  disclosure
statement pursuant to the Year 2000 Readiness and Disclosure Act.

     Boston   Biomedica's   Year  2000  program  is  designed  to  minimize  the
possibility  of serious Year 2000  interruption.  Possible  Year 2000 worst case
scenarios  include  the  interruption  of  significant  parts  of the  Company's
business as a result of internal  business  system failure or the failure of the
business  systems  of  its  suppliers,   distributors  or  customers.  Any  such
interruption  may have a material  adverse  impact on the future  results of the
Company.

     In 1997 the Company decided to significantly upgrade its "business systems"
(all  computer  hardware and software used to run its  businesses  including its
operations  management,  administration and financial  systems).  Specifications
were developed for desired capabilities, including Year 2000 compliance. In 1998
the Company began assessing its Year 2000 exposure and commenced  implementation
of a plan to  achieve  Year 2000  readiness.  Based on its  review to date,  the
Company believes that its products are Year 2000 compliant.

     During the third quarter of 1998, after investigating several alternatives,
implementation  of an enterprise  resource  planning  system ("ERP  system") was
started at two of the Company's  four sites.  The 

                                       8

<PAGE>


vendor has  certified  that the system is Year 2000  compliant.  In April  1999,
business systems at the other two sites were upgraded to Y2K compliant  versions
of their existing software at a combined cost of approximately $5,000.

     A task force with  participants  and a site leader at each BBI location has
begun reviewing all other infrastructure areas including communications systems,
building security systems, and embedded technologies in areas such as laboratory
instruments and  manufacturing  equipment.  The Company has also begun to survey
major  suppliers,  distributors,  and  customers  to  determine  the  status and
schedule for their Year 2000  compliance.  To date, no  significant  issues have
been identified, and the survey is expected to be completed in the third quarter
of  1999.  Where  it  believes  that a  particular  supplier's  situation  poses
unacceptable risks, the Company plans to identify an alternative source.

     The  costs  of  the   readiness   program  for  business   systems,   other
infrastructure  areas,  and suppliers  and  distributors  are a  combination  of
incremental external spending and use of existing internal resources.  In total,
the Company expects to spend less than $150,000 to achieve  readiness,  of which
approximately  60% has been expended to date.  This amount is based on the costs
to upgrade the existing business systems to Y2K compliant versions, and excludes
the costs of implementing the ERP system which is being  implemented for reasons
beyond Y2K compliance.

     Milestones  and  implementation  dates  and the  costs of BBI's  Year  2000
readiness  program are  subject to change  based on new  circumstances  that may
arise or new  information  becoming  available  that may change  the  underlying
assumptions or requirements.

Forward-Looking Statements

     This  Quarterly  Report on Form 10-Q  contains  forward-looking  statements
concerning the Company's  financial  performance  and business  operations.  The
Company  wishes to caution  readers of this  Quarterly  Report on Form 10-Q that
actual   results   might  differ   materially   from  those   projected  in  any
forward-looking statements.

     Factors which might cause actual  results to differ  materially  from those
projected  in  the  forward-looking  statements  contained  herein  include  the
following:  inability  of the Company to develop the end user market for quality
control  products;  inability of the Company to integrate the business of Source
Scientific,  Inc. into the Company's business;  inability of the Company to grow
the sales of Source  Scientific,  Inc.  to the  extent  anticipated;  failure to
obtain the renewal and full funding of contracts  with  National  Institutes  of
Health  (NIH),  National  Heart,  Lung and  Blood  Institute  (NHLBI)  and other
government  agencies;  the possibility that the Company may not be successful in
commercializing current R&D projects, may not have the resources to complete the
projects,  or that the  projects  may take  longer than  expected  to  complete;
inability  of the  Company to obtain an  adequate  supply of the unique and rare
specimens of plasma and serum necessary for certain of its products; significant
reductions  in  purchases  by  any  of  the  Company's  major   customers;   the
interruption  of  significant  parts of the  Company's  business  as a result of
internal  business system failure or the failure of the business  systems of its
suppliers,  distributors  or customers  due to the  inability of such systems to
properly  interpret  dates  subsequent  to December 31, 1999;  and the potential
insufficiency of Company resources,  including capital,  human resources,  plant
and equipment and management systems, to accommodate any future growth.  Certain
of these and other factors which might cause actual results to differ materially
from those  projected are more fully set forth under the caption "Risk  Factors"
in the Company's Registration Statement on Form S-1 (SEC File No. 333-10759) and
in its most recent filing on Form 10-K for the year ended December 31, 1998.

                                       9

<PAGE>


    BOSTON BIOMEDICA, INC.

Part II. Other Information

Item 4. Submission of Matters to a Vote of Security Holders.

None

Item 6.   Exhibits and Reports on Form 8K
(a)      Exhibits

       Exhibit No.
       -----------
       3.1   Amended and Restated Articles of Organization of the Company**

       3.2   Amended and Restated Bylaws of the Company**

       4.1   Specimen Certificate for Shares of the Company's Common Stock**

       4.2   Description  of  Capital  Stock  (contained  in  the  Restated
             Articles of  Organization of the Company filed as Exhibit 3.1)**

       27    Financial Data Schedule

------------------------

**     In accordance with Rule 12b-32 under the Securities Exchange Act of 1934,
       as amended,  reference is made to the documents previously filed with the
       Securities   and  Exchange   Commission,   which   documents  are  hereby
       incorporated by reference.

(b)      Reports on Form 8K

         None

                                       10

<PAGE>




                                   SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  Report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.



                                    BOSTON BIOMEDICA, INC.



Date: May 14, 1999                  By /s/ KEVIN W. QUINLAN
     ----------------------------      -------------------------------------
                                       Kevin W. Quinlan, Chief Financial Officer
                                           (Principal Financial Officer)

                                       11

<PAGE>


                             BOSTON BIOMEDICA, INC.

                                  EXHIBIT INDEX

EXHIBIT INDEX
-------------

<TABLE>
<CAPTION>
   Exhibit No.                                                                  Reference
   -----------                                                                  ---------

<S>                                                                             <C>  
   3.1  Amended and Restated Articles of Organization of the Company              A**

   3.2  Amended and Restated Bylaws of the Company                                A**

   4.1  Specimen Certificate for Shares of the Company's Common Stock             A**

   4.2  Description of Capital Stock (contained in the Restated Articles of       A**
        Organization of the Company filed as Exhibit 3.1)

   27   Financial Data Schedule                                                 Filed herewith
</TABLE>

------------------------

A    Incorporated by reference to the Company's  Registration  Statement on Form
     S-1 (Registration No. 333-10759)(the  "Registration Statement"). The number
     set  forth  herein  is the  number  of the  Exhibit  in  said  registration
     statement.

**   In accordance  with Rule 12b-32 under the Securities  Exchange Act of 1934,
     as amended,  reference is made to the documents  previously  filed with the
     Securities and Exchange Commission, which documents are hereby incorporated
     by reference.

                                       12

<PAGE>